MOLOGEN has announced that its pivotal Phase III IMPALA trial testing lefitolimod as a maintenance therapy in patients with metastatic colorectal cancer (mCRC) has missed its primary endpoint of ov...
Original Article: MOLOGEN - IMPALA readout ends monotherapy strategy